Product Images Gabapentin
View Photos of Packaging, Labels & Appearance
- Creatinine clearance - gabapentin fig1
- Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1 - gabapentin fig2
- Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2 - gabapentin fig3
- Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies - gabapentin fig4
- Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - gabapentin fig5
- Chemical Structure - gabapentin str
- Label - lbl713352701
Product Label Images
The following 7 images provide visual information about the product associated with Gabapentin NDC 71335-2701 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Creatinine clearance - gabapentin fig1
This text appears to be a formula for calculating creatinine levels in the blood based on age and weight for both male and female patients, with a different constant value for females. The formula involves multiplying the age in years by the weight in kilograms and then dividing by a constant value. This calculation can help in assessing kidney function.*
Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1 - gabapentin fig2
This is a data visualization showing the Weekly Mean Pain Scores in a study comparing placebo and gabapentin at a dose of 300 mg/day. It illustrates the observed cases in the ITT Population over time.*
Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2 - gabapentin fig3
Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies - gabapentin fig4
Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - gabapentin fig5
Figure showing the difference from placebo in the efficacy of adjunctive therapy for individuals with partial seizures at 12 years of age. The graph displays the results at various daily doses ranging from 600 to 1800 mg.*
Chemical Structure - gabapentin str
Label - lbl713352701
The text provides information about Gabapentin tablets USP with a strength of 600 mg per film-coated tablet. It includes dosage instructions, storage conditions (20-25°C), and precautions (may cause dizziness, keep out of reach of children). The NDC for the tablets is 71335-2701-1, and they should be dispensed in a tight, child-resistant container. Further details can be found on the package insert or by scanning the QR code provided.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
